全文获取类型
收费全文 | 4202篇 |
免费 | 115篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 36篇 |
儿科学 | 71篇 |
妇产科学 | 26篇 |
基础医学 | 154篇 |
口腔科学 | 82篇 |
临床医学 | 573篇 |
内科学 | 1248篇 |
皮肤病学 | 93篇 |
神经病学 | 152篇 |
特种医学 | 90篇 |
外科学 | 414篇 |
综合类 | 219篇 |
预防医学 | 382篇 |
眼科学 | 54篇 |
药学 | 621篇 |
中国医学 | 65篇 |
肿瘤学 | 59篇 |
出版年
2024年 | 11篇 |
2023年 | 115篇 |
2022年 | 157篇 |
2021年 | 208篇 |
2020年 | 195篇 |
2019年 | 190篇 |
2018年 | 183篇 |
2017年 | 116篇 |
2016年 | 69篇 |
2015年 | 55篇 |
2014年 | 208篇 |
2013年 | 196篇 |
2012年 | 145篇 |
2011年 | 171篇 |
2010年 | 154篇 |
2009年 | 137篇 |
2008年 | 111篇 |
2007年 | 104篇 |
2006年 | 92篇 |
2005年 | 66篇 |
2004年 | 35篇 |
2003年 | 48篇 |
2002年 | 39篇 |
2001年 | 30篇 |
2000年 | 20篇 |
1999年 | 25篇 |
1998年 | 16篇 |
1997年 | 24篇 |
1996年 | 15篇 |
1995年 | 13篇 |
1994年 | 11篇 |
1993年 | 9篇 |
1992年 | 9篇 |
1990年 | 7篇 |
1988年 | 7篇 |
1987年 | 8篇 |
1986年 | 7篇 |
1985年 | 63篇 |
1984年 | 132篇 |
1983年 | 151篇 |
1982年 | 120篇 |
1981年 | 113篇 |
1980年 | 119篇 |
1979年 | 112篇 |
1978年 | 118篇 |
1977年 | 55篇 |
1976年 | 102篇 |
1975年 | 81篇 |
1974年 | 92篇 |
1973年 | 68篇 |
排序方式: 共有4339条查询结果,搜索用时 15 毫秒
101.
Li-Ye Wei Xiang-Hua Fu Wei Li Xi-Le Bi Shi-Ru Bai Kun Xing Yan-Bo Wang 《中华医学杂志(英文版)》2015,128(9):1147-1150
Background:
Several studies have demonstrated that primary percutaneous coronary intervention (PCI) can result in reperfusion injury. This study aims to investigate the effectiveness of liposomal prostaglandin E1 (Lipo-PGE1, Alprostadil, Beijing Tide Pharmaceutical Co., Ltd.) for enhancing microcirculation in reperfusion injury. In addition, this study determined the optimal administration method for acute ST elevation myocardial infarction (STEMI) patients undergoing primary PCI.Methods:
Totally, 68 patients with STEMI were randomly assigned to two groups: intravenous administration of Lipo-PGE1 (Group A), and no Lipo-PGE1 administration (Group B). The corrected thrombolysis in myocardial infarction (TIMI) frame count (cTFC) and myocardial blush grade (MBG) were calculated. Patients were followed up for 6 months. Major adverse cardiac events (MACE) were also measured.Results:
There was no significant difference in the baseline characteristics between the two groups. The cTFC parameter in Group A was significantly lower than Group B (18.06 ± 2.06 vs. 25.31 ± 2.59, P < 0.01). The ratio of final MBG grade-3 was significantly higher (P < 0.05) in Group A (87.9%) relative to Group B (65.7%). There was no significant difference between the two groups in final TIMI-3 flow and no-reflow. Patients were followed up for 6 months, and the occurrence of MACE in Group A was significantly lower than that in Group B (6.1% vs. 25.9% respectively, P < 0.05).Conclusions:
Myocardial microcirculation of reperfusion injury in patients with STEMI, after primary PCI, can be improved by administering Lipo-PGE1. 相似文献102.
American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis 总被引:17,自引:0,他引:17
Parkman HP Hasler WL Fisher RS;American Gastroenterological Association 《Gastroenterology》2004,127(5):1592-1622
This literature review and the recommendations herein were prepared for the American Gastroenterological Association Clinical Practice Committee. The paper was approved by the Committee on May 16, 2004, and by the AGA Governing Board on September 23, 2004. 相似文献
103.
104.
105.
106.
107.
《JACC: Cardiovascular Interventions》2014,7(8):923-933
ObjectivesThe aim of this study was to assess the safety and effectiveness of directional atherectomy (DA) for endovascular treatment of peripheral arterial disease (PAD) in infrainguinal arteries in patients with claudication or critical limb ischemia.BackgroundTo date, no prospective, multicenter, independently-adjudicated study has evaluated the effectiveness and durability of DA in the treatment of PAD. Previous DA studies have not been prospectively powered to evaluate any differences in outcomes in patients with and without diabetes.MethodsDEFINITIVE LE (Determination of EFfectiveness of the SilverHawk® PerIpheral Plaque ExcisioN System (SIlverHawk Device) for the Treatment of Infrainguinal VEssels / Lower Extremities) prospectively enrolled subjects at 47 multinational centers with an infrainguinal lesion length up to 20 cm. Primary endpoints were defined as primary patency at 12 months for claudicants and freedom from major unplanned amputation for critical limb ischemia (CLI) subjects. A pre-specified statistical hypothesis evaluated noninferiority of primary patency in diabetic versus nondiabetic claudicants. Independent angiographic and sonographic core laboratories assessed outcomes, and events were adjudicated by a clinical events committee.ResultsA total of 800 subjects were enrolled. The 12-month primary patency was 78% (95% confidence interval: 74.0% to 80.6%) in claudicants, with a 77% rate in the diabetic subgroup versus 78% in the nondiabetic subgroup (noninferior, p < 0.001). The rate of freedom from major unplanned amputation of the target limb at 12 months in CLI subjects was 95% (95% confidence interval: 90.7% to 97.4%). Periprocedural adverse events included embolization (3.8%), perforation (5.3%), and abrupt closure (2.0%). The bail-out stent rate was 3.2%.ConclusionsThe DEFINITIVE LE study demonstrated that DA is a safe and effective treatment modality at 12 months for a diverse patient population with either claudication or CLI. Furthermore, DA was shown to be noninferior for treating PAD in patients with diabetes compared with those without diabetes. (Study of SilverHawk/TurboHawk in Lower Extremity Vessels [DEFINITIVE LE]; NCT00883246). 相似文献
108.
109.
110.